We recently reported the association between the baseline circulating MMP2 level and, to a lesser extent, the MMP9 level, and the response rate, PFS and OS of patients treated with bevacizumab for recurrent high-grade glioma [8]. This evidence concerns the gene MMP2 and central nervous system cancer.